Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 4/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.46 |
| ▸ | AR | P10275 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22383643 | 0.80 | MTNR1A (0.43) | GAAMAPTBRD4CREBBP | |
| SCHEMBL16169476 | 0.80 | GAA (0.49) | GAAMAPTBRD4CREBBPAR | |
| SCHEMBL33268 | 0.78 | CREBBP (0.55) | GAAMAPTBRD4CREBBPAR | |
| SCHEMBL1736809 | 0.78 | CREBBP (0.55) | GAAMAPTBRD4CREBBPAR | |
| SCHEMBL12837999 | 0.78 | CREBBP (0.55) | GAAMAPTBRD4CREBBPAR | |
| SCHEMBL29572486 | 0.78 | CREBBP (0.55) | GAAMAPTBRD4CREBBPAR | |
| SCHEMBL1868013 | 0.78 | CREBBP (0.55) | GAAMAPTBRD4CREBBPAR | |
| SCHEMBL21172542 | 0.77 | GAA (0.42) | GAAMAPTBRD4CREBBPAR | |
| SCHEMBL21172557 | 0.77 | GAA (0.42) | GAAMAPTBRD4CREBBPAR | |
| SCHEMBL13306140 | 0.77 | GAA (0.46) | GAAMAPTBRD4CREBBPAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9748044-B2 | Photosensitizer and photoelectric conversion device | CHEMICREA INC. (JP) | 2017-08-29 | — | — | US | disclosed |
| US-20170092436-A1 | PHOTOSENSITIZER AND PHOTOELECTRIC CONVERSION DEVICE | CHEMICREA INC. (JP) | 2017-03-30 | — | — | US | disclosed |
| US-8741924-B2 | Compounds and methods for treatment of systemic lupus erythematosus | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130123299-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123299-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS | SSB, DNASE1L3, SNRPD2 | GAA 1281/4885MAPT 4658/4885BRD4 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.